Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale Academic Article uri icon

Overview

MeSH Major

  • DNA, Neoplasm
  • Germ-Line Mutation
  • Neoplasms

abstract

  • We describe the rationale and design of the CLEAR study, a three-arm Phase III trial comparing lenvatinib plus everolimus and lenvatinib plus pembrolizumab versus sunitinib monotherapy for first-line treatment of RCC. Eligible patients must have advanced clear cell RCC and must not have received any prior systemic anticancer therapy. The primary end point is progression-free survival; secondary end points include objective response rate, overall survival, safety, health-related quality of life and pharmacokinetics. Biomarker evaluations are included as exploratory end points.

publication date

  • March 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.2217/fon-2018-0745

PubMed ID

  • 30689402

Additional Document Info

start page

  • 929

end page

  • 941

volume

  • 15

number

  • 9